Slide 1: Exchange filing cover letter for Q2FY25 analyst presentation
INDGN/SE/2024-25/57 October 28, 2024 BSE Limited, National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai- 400001, India. Mumbai – 400 051, India. Scrip Code: 544172 Trading symbol: INDGN Dear Sir / Mada
Slide 2: Investor Presentation October 2024
Investor Presentation October 2024
Slide 3: Disclaimer
Disclaimer This presentation may include opinions and assumptions about future performance which could be considered as forward-looking statements. Forward-looking statements intrinsically cover several risks and uncertainties, which may lead to a material difference between actual results and the s
Slide 4: We operate at the intersection of healthcare and technology
We operate at the intersection of healthcare and technology Healthcare Tech-Led Delivery and Expertise Digital Capabilities Healthcare market understanding Digital-first approach In-depth domain knowledge Gen AI based tools and platform Navigating regulatory landscape Drive transformation Medical co
Slide 5: We are a Digital First Commercialization Partner
We are a Digital First Commercialization Partner We We Provide Provide Capabilities Capabilities and and Expertise Expertise Across Across the the Commercialization Commercialization Value Value Chain Chain Regulatory and R&D / Clinical and Marketing and Sales Pharmacovigilance Medical Affairs Other
Slide 6: Our large addressable market is underpinned by growing outsourcing and rapid digital adoption
Our large addressable market is underpinned by growing outsourcing and rapid digital adoption Outsourcing and Tech Lifesciences at Inflection We Offer Solutions Large Market Opportunity Expanding our TAM Point Across Life Sciences End Markets Life Sciences Operations Spend Across Verticals ($B) ~9-1
Slide 7: Management Commentary on Q2FY25 results
Management Commentary on Q2FY25 results Manish Gupta, Chairman and Chief Executive Officer – In Q2FY25, we achieved revenue growth of 8.0% YoY. The growth is largely driven by positive momentum in both big and mid-size pharma customers. Our largest customer, which was approximately USD 42 million in
Slide 8: Q2 FY25: Business Highlights
Q2 FY25: Business Highlights INR 6,868 Mn 8.0% 6.6% Significant YoY revenue growth in YoY revenue growth in Revenue from Operations growth at scale INR terms USD terms 68 37 68% Strong client Active Client Relationships Clients with $1 Million+ Revenue from Top 20 relationships Revenue Global Biopha
Slide 9: Q2 FY25: Quarter Summary
Q2 FY25: Quarter Summary Amount in INR Mn Particulars Q2 FY25 Q2 FY24 YoY % H1 FY25 H1 FY24 YoY % Revenue from Operations 6,868 6,357 8.0% 13,633 12,432 9.7% Enterprise Medical Solutions 1,977 1,474 34.1% 3,866 2,884 34.0% Enterprise Commercial Solutions 3,863 3,790 1.9% 7,612 7,462 2.0% Omnichannel
Slide 10: Long-standing and highly sticky client relationships
Long-standing and highly sticky client relationships 68 22 20 of Top 20 68% Active clients(1) Active clients (1) added Global biopharma Revenue from top 20 global FY2022 to Q2FY25 companies as clients (2) biopharma companies(2) Successful track record of growing accounts # Growing active client base
Slide 11: Business mix
Business mix Revenue from Service offering ($Mn) Revenue by Customer Industry (%) Revenue by Customer Geography (%) 76.9 81.1 82.0 3% 2% 2% 1% 1% 6% 4% 3% 12% 27% 12% 12% Q2FY25 Q2FY25 55% 56% 60% 70% 94% 23% 28% 29% Q2FY24 Q1FY25 Q2FY25 Enterprise Medical Solutions Enterprise Commercial Solutions B
Slide 12: Financial Highlights
Financial Highlights © 2024 Indegene. All rights reserved. 11
Slide 13: Q2 FY25 Consolidated Financials
Q2 FY25 Consolidated Financials Amount in INR Mn Particulars Q2 FY25 Q1 FY25 Q2 FY24 QoQ % YoY % H1 FY25 H1 FY24 YoY % Revenue from Operations 6,868 6,765 6,357 1.5% 8.0% 13,633 12,432 9.7% Employee Benefit Expenses 4,420 4,443 4,056 -0.5% 9.0% 8,863 8,101 9.4% Other Expenses 1,187 1,033 1,090 14.9%
Slide 14: Healthy margin profile and robust balance sheet
Healthy margin profile and robust balance sheet EBITDA and EBITDA Margin(1) PAT and PAT Margin Cash and Cash Equivalent(2) INR Mn and % INR Mn and % INR Mn 19.6% 13.0% 13.4% 18.4% 11.8% 19.2% 13,973 14,666 1,328 877 917 1,267 750 1,224 8,148 Q2FY24 Q1FY25 Q2FY25 Q2FY24 Q1FY25 Q2FY25 Q2FY24 Q1FY25 Q2
Slide 15: Indegene Digital Summit 2024
Indegene Digital Summit 2024 • Sixth edition, with 50+ industry-leading speakers • Featured practitioners' perspectives on Generative AI, Advanced Analytics, Technology and Operations Transformation • One of the most anticipated annual events in life sciences globally • Promotes idea exchange, colla
Slide 16: Awards and Recognitions
Awards and Recognitions Best Companies for Women in India 2024: Professional Services Best Companies for Women in India 2024: Hall of Fame – 5 Years in Best Companies Silver Stevie for Technology Bronze Stevie for Technology Excellence Excellence Technical Innovation of the Year Technology Breakthro
Slide 17: Thank you
Thank you indegene’
Slide 18: Fact Sheet
Fact Sheet Consolidated Financial Data - Second Quarter, Fiscal 2025 Operational & Financial Metrics Key performance indicators (in INR Mn) Quarter ended Growth SI. Particulars Sept 30, June 30, Sept 30, No. YoY QoQ 2024 2024 2023 1. Active clients(1)(No.) 68 65 63 2. Revenue from operations 6,868 6
Slide 19: Fact Sheet
Fact Sheet Consolidated Financial Data - Second Quarter, Fiscal 2025 Revenue by customer industry (in %) Quarter ended (contribution) Growth Particulars Sept 30, June 30, Sept 30, YoY QoQ 2024 2024 2023 Biopharma 94.1 93.5 93.0 9.3 2.2 Medical Devices 2.4 2.7 3.3 -22.8 -13.0 Emerging Biotech 2.6 2.6